Emerging as a significant advance in the battle against obesity, Retatrutide is capturing considerable attention . It combines the action of two known GLP-1 receptor agonists, liraglutide, with an additional glucose-dependent incretin component. Initial clinical data have demonstrated significant weight decrease in patients with a high BMI , perhap